USRE35893E - Defoaming composition - Google Patents
Defoaming composition Download PDFInfo
- Publication number
- USRE35893E USRE35893E US08/374,224 US37422495A USRE35893E US RE35893 E USRE35893 E US RE35893E US 37422495 A US37422495 A US 37422495A US RE35893 E USRE35893 E US RE35893E
- Authority
- US
- United States
- Prior art keywords
- agglomerates
- maltodextrin
- composition
- antifoaming
- defoaming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D19/00—Degasification of liquids
- B01D19/02—Foam dispersion or prevention
- B01D19/04—Foam dispersion or prevention by addition of chemical substances
- B01D19/0404—Foam dispersion or prevention by addition of chemical substances characterised by the nature of the chemical substance
Definitions
- This invention relates to a composition whereby fluid, nonaqueous, defoaming or antifoaming compositions are prepared as relatively free flowing granular combinates by intermixing them with a low density, highly porous, generally spherical, water soluble carbohydrate-based agglomerate such as maltodextrin to form adjuvant agglomerate combinates suitable for addition to product or processes wherever a rapid dispersion of the antifoaming or defoaming compound in an aqueous medium is indicated or desired.
- Fluid hydrocarbon oil-based antifoaming or defoaming compositions containing a hydrocarbon-silicon copolymer, a hydrophobic filler, an organo-silicone surfactant, a hydrocarbon carrier oil, and, optionally, a silicone oil are disclosed in Kulcarni et al U.S. Pat. No. 4,514,319.
- Fluid antifoaming or defoaming compositions comprising mineral oil-containing dispersed hydrophobic solid particles are well known in the art.
- hydrophobic silica in fluid hydrocarbon oil based antifoam or defoaming compositions is disclosed in U.S. Pat. Nos. 3,076,768; 3,207,698; 3,388,073; and 3,714,068.
- Fluid antifoaming or defoaming compositions comprising polyoxyethylene-polypropylene copolymers containing dispersed hydrophobic silica are disclosed in U.S. Pat. Nos 3,912,652 and 3,959,176.
- Fluid antifoaming or defoaming compositions in a non-silicone oil and containing activated insitu hydrophobic silica particles are disclosed in U.S. Pat. No. 3,304,266.
- Fluid antifoaming or de foaming compositions comprising a non-silicone water insoluble polyalkylene containing an alkoxysilicon chloride as the hydrophobic agent are disclosed in G.B. Pat. No. 1,166,877.
- Fluid antifoaming or defoaming compositions employing the use of other intrinsically hydrophobic fillers in organic liquids are also well known.
- Canadian Pat. No. 508,856 discloses N,N'-distearyl ethylene-diamide in white spirits, while the use of finely divided polyolefin polymers or polyesters dispersed in organic liquids is disclosed in U.S. Pat. No. 3,705,859.
- the use of fatty acid salts is disclosed in G.B. Pat. No. 1,267,482 and low molecular weight polyethylenes in combination with mineral oil and conventional organic nonionic emulsifiers is disclosed in U.S. Pat. No. 3,909,445.
- Fluid antifoam or defoaming compositions comprising silicone oil-silica compounds containing organo silicone compounds to improve performance are disclosed in U.S. Pat. No. 3,691,091.
- Fluid antifoam or defoaming compositions comprising the use of silicone-glycol copolymers in association with silicone oil and silica are disclosed in U.S. Pat. Nos. 3,746,653; 3,784,479; and 3,865,544.
- Simethicone is a fluid antifoam or defoaming composition comprised of polydimethylsiloxane and silica suitably purified for its intended application.
- the preparation of liquid methylsiloxane polymers is delineated in U.S. Pat. No. 2,441,098, the disclosure of which is hereby incorporated by reference.
- the normal physical state of the simethicone Is a water white to grey translucent, viscous, oil-like liquid with a density of 0.965-0.970 grams/cubic centimeter having demonstrable immiscibility with water and alcohol.
- simethicone is as an ointment base ingredient, topical drug vehicle, skin protectant, but most particularly as an antigas and antiflatulent agent for human application as well as an antibloating agent for veterinary (animal) application.
- a combinate of simethicone and calcium silicate useful for such latter applications is disclosed in Valentine et al. U.S. Pat. No. 4,906,478.
- Non-pharmaceutical and non-medicinal antifoaming applications such as powdered leaning agents, are disclosed in Farminer et al U.S. Pat. No. 3,843,558; Llenado U.S. Pat. No. 4,180,485; Abel U.S. Pat. No. 4,264,465; Matheson et al U.S. Pat. No. 4,102,823; and European Patent 213,953 to Iley et al.
- the preferred pharmaceutical solid dose delivery system for simethicone is a chewable tablet
- Such chewable tablets often contain antacid ingredients such as calcium carbonate, aluminum hydroxide, magnesium hydroxide and magnesium carbonate.
- antacid ingredients such as calcium carbonate, aluminum hydroxide, magnesium hydroxide and magnesium carbonate.
- the article by F. Maksond et al, "Simethicone use in Antacid Medications" as published in Manufacturing Chemist and Aerosol News, Vol. 47, No. 5, 1976, pp 36-36 discloses instability problems when simethicone is intermixed with aluminum or magnesium bases It is extremely troublesome to distribute the oil-like, viscous, water and alcohol immiscible simethicone expeditiously and uniformly throughout a tablet granulation prior to compression. It is equally difficult to be certain that the simethicone is in a sufficiently divided and dispersed state so that its action will be quick and effective when administered per os as a chewable or swallowable tablet or powder filled
- the present invention achieves these objects and satisfies the long felt need to overcome the difficulties in expedeitious utilization of antifoaming or defoaming compounds in an aqueous medium
- a larger amount of antifoaming or defoaming compound can be incorporated with the carbohydrate-based agglomerate of this invention for dispersion than has previously been disclosed in the prior art.
- the carbohydrate-based agglomerate portion of the combinate makes it possible to effect rapid and uniform distribution of the antifoaming/defoaming compound by simple mixing.
- the present invention relates to fluid, nonaqueous, antifoaming or defoaming compositions prepared as a dry, solid, flowable granule by intermixing a fluid, nonaqueous, antifoaming or defoaming compound or composition and a low density, highly porous, generally spherical, water soluble, carbohydrate-based agglomerate such as a maltodextrin agglomerate, maltodextrin/dextrose co-agglomerate, dextrose agglomerate, maltodextrin/sucrose co-agglomerate, maltodextrin/fructose co-agglomerate, sucrose agglomerate, fructose agglomerate, mannitol agglomerate, sorbitol agglomerate, agglomerated hydrolyzed cereal solids, agglomerated corn syrup solids, and combinations thereof to form a functional combinate.
- the preferred agglomerate is maltodextrin, a low conversion starch hydrolyzate having a D.E. (dextrose equivalent) less than 20.
- the fluid, nonaqueous, antifoaming or defoaming compound or composition is added, in liquid form, to the water soluble carbohydrate agglomerate and blended to form a uniform, relatively free flowing combinate in which the base structure is water soluble.
- the combinate may be readily added to conventional products and processes where a rapid dispersion of the fluid, nonaqueous, antifoaming or defoaming compound is indicated.
- the fluid, nonaqueous, antifoaming or defoaming combinate have from about 10 to 50 weight percent antifoaming or defoaming composition or compound, and from about 90 to 50 weight percent carbohydrate agglomerate. It is more preferred that the fluid, nonaqueous, antifoaming or defoaming composition or compound represents 30 weight percent and the water soluble, highly porous, low density, generally spherical, carbohydrate agglomerate represents 70 weight percent of the admixture combinate. Unless otherwise specified, all references to percentages are in weight percent.
- the terms "antifoaming" and “defoaming” are generally used interchangably throughout the specification.
- the antifoaming compositions or compounds useful in this invention may be any of those discussed in the background section of the specification, particularly simethicone (for pharmaceutical and medicinal applications) and silicone, mineral or other oils containing silica.
- the preferred fluid, nonaqueous, antifog or defoaming compound prepared as a flowable granule used herein is simethicone and, more specifically, simethicone U.S.P. as defined in the United States Pharmacopeia, incorporated herein by reference, which has the chemical structure:
- Simethicone is a mixture of fully methylated linear siloxane polymers containing repeating units of the formula --(CH 3 ) 2 SiO--! n , stablilized with trimethylsiloxy end-blocking units of the formula (CH 3 ) 3 SiO--!, and silicon dioxide. It is preferred to contain not less than 90.5 percent and not more than 99.0 percent of polydimethylsiloxane ( -(CH 3 ) 2 SiO--!n)), and not less than 4.0 percent and not more than 7.0 percent of silicon dioxide.
- Maltodextrins are composed of water soluble glucose polymers obtained from the reaction of starch with acid and/or enzymes in the presence of water.
- the starch is hydrolyzed to produce hydrolyzate products containing sugars.
- the production of starch hydrolyzates, and, in particular, low conversion starch hydrolyzates, is described in U.S. Pat. Nos. 3,663,369; 3,849,194; 4,298,400; and U.S. Pat. No. Re. 30,880, the disclosures of which are hereby incorporated by reference.
- the starch used for the preparation of maltodextrins can be any of a variety of commercially available starches such as maize, potato, or tapioca. Further, the U.S.
- maltodextrins (C 6 H 12 O 5 ) n H 2 O, as nonsweet nutritive saccharide polymers that consist of D-glucose units linked primarily by alpha 1-4 bonds and having a D.E. (total reducing sugars expressed as dextrose equivalents) of less than 20.
- Maltodextrin is usually produced as a fine, white powder and is generally recognized as safe (gras) as a direct human food ingredient at levels consistent with good manufacturing practices.
- Agglomerated maltodextrin is available from a variety of commercial sources and in a larger, more porous, faster dissolving, and more free flowing form.
- the preferred commercial source for low density, highly porous, generally spherical, water soluble maltodextrin agglomerates is the product family sold by Valentine Enterprises, Inc of Lawrenceville, Georgia under the trademark VELite.
- the preferred VELite is VELite 20/40 which is prepared from 9-12 D.E. maltodextrin, derived from corn starch, and having the following typical analysis: a particle size distribution of about 100 percent less than 850 microns and a majority (98 percent) greater than 420 microns; an apparent density of from about 10 to about 12 pounds per cubic foot; a maximum moisture content of 6 percent; and a total surface area of between about 9.5 ⁇ 1 and 10.5 ⁇ 1 square meters per gram as determined by a 3 point nitrogen B.E.T. analysis.
- a preferred embodiment of the present invention is directed toward the admixture of simethicone and maltodextrin agglomerate to form a uniform, relatively free flowing, granular combinate containing 30 percent by weight of simethicone and 70 percent by weight maltodextrin for incorporation into tablets or for use "as is" for addition to an aqueous medium whenever antifoaming or defoaming is desired.
- simethicone/70 percent by weight agglomerated maltodextrin combinate is readily formulated into, for example, antacid or antigas formulations by adding the 30% simethicone active granule combinate to a compressible granule base without sacrificing or compromising the compressibility of the base granule. It is a further feature of the present invention that the simethicone is contained in or on a water soluble agglomerated maltodextrin and, as such, is available and stable in the formulations
- the process of the present invention may be practiced by obtaining desired quantities of agglomerated maltodextrin, such as VELite 20/40 available from Valentine Enterprises, Inc, and consumable simethicone, such as Sentry simethicone available from Union Carbide Corporation. These two starting materials are then mixed employing low shear mixing such as that encountered in a planetary, ribbon or plow mixer in order to effect a uniform combinate agglomerate suitable for use without further processing
- the relative amounts of the simethicone and the maltodextrin agglomerate may range from about 10 to about 50 weight percent simethicone and from about 90 to about 50 percent by weight of agglomerated maltodextrin This range of the ingredients has been found to provide optimum performance of the final simethicone/agglomerated maltodextrin combinate. If more than about 50% by weight percent simethicone is used, the product tends to be too moist and exhibits poor flow. If more than 90% by weight of agglomerated maltodextrin is used the product tends to exhibit non-uniform distribution of the simethicone. Exceeding either extreme will tend to result in less than optimum product performance, most particularly in final tableting. A 30% by weight simethicone to 70% by weight agglomerated maltodextrin ratio represents the preferred product performance whether for tableting or for general purpose aqueous antifoaming or defoaming application.
- the combinate maltodextrin and the antifoaming or defoaming composition preferably has a particle size in which essentially all of the particles are less than about 20 mesh (-20 mesh) and greater than 40 mesh (+40 mesh) and a total typical surface area of less than about 1 square meter per gram.
- the antifoaming and/or defoaming containing adjuvant combinate granules of the present invention have been found to be equal in foam inhibition and foam breaking to an equivalent quantity of the starting simethicone. This means, for example, that 66.7 mg of the 30% simethicone combinate granule is equivalent in performance to 20 mg of simethicone The equivalent performance is demonstrable even after the simethicone/agglomerated maltodextrin combinates have been stored at 45.C for a period of two months.
- Defoaming activity of the simethicone/agglomerated maltodextrin combinate or of the monadic simethicone or of the simethicone/agglomerated maltodextrin combinate contained as part of an antacid and/or antigas tablet i.e., foam breaking (defoaming) and/or foam inhibition (antifoaming)
- foam breaking (defoaming) and/or foam inhibition may be defined and measured by the procedure given in the United States Pharmacopeia.
- foaming solution and test preparation are prepared as follows:
- Foaming solution--dissolve 1 g of octoxylnol 9 in 100 ml of distilled water.
- the procedure for determining defoaming activity as follows: For each test, a clean, unused 250 ml glass jar fitted with a 50 mm cap should be employed. Add, dropwise, 0.5 ml of the test preparation (i.e., equivalent to 2.0 mg simethicone) to the 250 ml glass jar containing 100 ml of the foaming solution. Cap the jar and clamp it in an upright position on a wrist action shaker. Employing a radius of 13.3 ⁇ 0.4 cm (measured from the center of the shaft to the center of the bottle), shake for 10 seconds through an arc of 10° at a frequency of 300 ⁇ 30 strokes per minute. Record the time required for the foam to collapse.
- the test preparation i.e., equivalent to 2.0 mg simethicone
- the time, in seconds, for foam collapse is determined at the instant the first portion of foam-free liquid surface appears, measured from the end of the shaking period. This time is the defoaming activity time and should not exceed 15 seconds for acceptable simethicone activity.
- a quantity of the combinate equivalent to 2.0 mg of simethicone i.e. 67 mg of a 30% simethicone/maltodextrin combinate is introduced directly into the test solution and the defoaming time is determined as described above.
- simethicone supplied by the simethicone/maltodextrin combinate, which must be used to prepare an antacid/antigas preparation.
- a typical formulation would contain:
- simethicone/agglomerated maltodextrin adjuvant combinate demonstrates itself as a uniquely stable product capable of being combined with antacid ingredients such as aluminum and magnesium bases in a single layer tablet without compromising the acid neutralizing or the defoaming or antifoaming capacity of the dose form.
- Standard excipients can be combined with the simethicone/agglomerated maltodextrin combinate granules in order to prepare pharmaceutical preparations in the form of tablets or capsules.
- the simethicone/agglomerated maltodextrin combinate may be combined and blended with standard compression granules comprising, for example, calcium carbonate, dextrose, sucrose mannitol, sorbitol, aluminum hydroxide dried gel, magnesium hydroxide, any compatible spray dried flavor, and magnesium stearate.
- the blended preparation may be pressed by standard, well known techniques to form tablets of desired weight, potency, and hardness.
- a single layer homogeneous unit dosage tablet or capsule may preferably contain from about 80 mg to about 280 mg of the simethicone/agglomerated maltodextrin combinate (i.e., from about 25 to about 80 mg of simethicone), but any desired amount outside this range may be used for specific applications.
- mannitol agglomerate sorbitol agglomerate, agglomerated hydrolyzed cereal solids, and agglomerated corn syrup solids, i.e., those having a D.E. of 20 or greater
- Any of these agglomerates, either alone or in combination, may be obtained, combined with simethicone, and utilized in the same manner as described above for the embodiment utilizing agglomerated maltodextrin alone.
- the combinate will preferably comprise at least about 50 weight percent, and up to about 90 weight percent, of the carbohydrate-based agglomerate.
- the particle size of substantially all of the carbohydrate- based agglomerate is preferably less than about 850 microns, with the majority (up to about 98 wt. %) greater than about 420 microns.
- the maltodextrin/dextrose, maltodextrin/sucrose and maltodextrin/fructose co-agglomerates are preferably prepared by well known fluid bed agglomeration techniques in which maltodextrin in solution (e.g., a 10% aqueous solution or 5% povidone (K 29/32) U.S.P. solution) is combined with the dextrose, sucrose or fructose in an agglomerator bed.
- maltodextrin in solution e.g., a 10% aqueous solution or 5% povidone (K 29/32) U.S.P. solution
- K 29/32 10% aqueous solution
- sucrose or fructose e.g., 5% povidone (K 29/32) U.S.P. solution
- the specific ratio of maltodextrin to dextrose, sucrose or fructose may vary according to use, and may be determined without undue experimentation.
- the co-agglomerate is produced by standard spray granulation techniques
- the carbohydrate-based agglomerates will preferably have a particle size range of less than 20 mesh and greater than 60 mesh (U.S. Standard), more preferably less than 20 mesh and greater than 40 mesh.
- compositions or compounds useful in this invention with maltodextrin or any of the other aforementioned carbohydrate-based agglomerates may be any of those organic liquid defoamers discussed in the background section of the specification, including hydrocarbon-based liquids, such as mineral oils and other hydrocarbon oil-based liquids, and silicone oils. These liquids may optionally contain silica
- the carbohydrate-based agglomerate and liquid antifoaming composition may be mixed by low shear mixing techniques in a planetary, ribbon or plow mixer in order to effect a uniform combinate agglomerate suitable for use without further processing.
- the combinate will preferably comprise at least about 10 weight percent, and no greater than about 50 weight percent, of the liquid antifoaming composition.
- Lower amounts or liquid antifoaming composition may be employed, although there tends to be non-uniform distribution of the antifoaming agent in amounts less than about 10 wt. %.
- the particle size range of the combinate is not substantially different from the particle size range of the carbohydrate-based agglomerate prior to mixing with the liquid antifoaming composition.
- the combinate of carbohydrate-based agglomerate and antifoaming or defoaming composition of the present invention may be used by contacting the aqueous medium in which defoaming is desired with the combinate.
- the carbohydrate-based agglomerate/simethicone combinate would be ingested by the user in tablet, capsule, granule or other unit dose form to provide antigas and/or antiflatulent treatment.
- the combinate may be prepared as granules in bulk filled packages or in unit dose forms such as compressed tablets or water soluble pouches for application to the aqueous medium.
- Acid neutralizing capacity may be measured by the procedure set forth in the United States Pharmacopeia.
- the analytical procedure, to be conducted at 37° C. ⁇ 3° C., is as follows:
- test preparations are prepared as follows: powders--transfer the accurately weighed portion of the substance to be tested to a 250 ml beaker, add 70 ml of water, and mix in the magnetic stirrer for one minute. Tablets--weigh not less than 20 tablets and determine the average tablet weight Grind the tablets to a powder that passes through a no. 20 sieve and is retained on a 100 sieve. Mix the material on the no. 100 sieve to obtain a uniform mixture, transfer an accurately weighed quantity of it, equivalent to the minimum dosage, to a 250 ml beaker. If wetting is desired, add not more than 5 ml of alcohol (neutralized to an apparent pH of 3.5), and mix to wet the specimen thoroughly. Add 70 ml of water, and mix on the magnetic stirrer for one minute.
- test procedure is as follows: Pipet 30.0 ml of 1.0N hydrochloric acid vs into the test preparation prepared earlier while continuing to stir with the magnetic stirrer. Magnetic stirring should continue for 15 minutes (accurately timed) after the addition of the acid. Thereafter, begin to titrate immediately, in a period not to exceed 5 minutes, the excess hydrochloric acid with 0.5N sodium hydroxide vs to attain a stable pH of 3.5 for not less than 15 seconds. Calculate the number of mEq of acid consumed per gram of the substance tested. Each ml of 1.0N hydrochloric acid is equal to 1 mEq of acid consumed.
- the VELite 20/40 was charged into a 1000 cc stainless steel beaker and the simethicone was added. The total materials were blended with a spatula until uniform. The resulting granular combinate was lump free, less than 850 microns (20 mesh) in size, and contained 20% simethicone.
- the VELite 20/40 was charged into a 5000 ml stainless steel beaker and the simethicone was added. The total materials were blended with a spatula until uniform. The resulting granular combinate was lump free, less than 850 microns (20 mesh) in size and contained 30% simethicone.
- VELite 20/40 was charged into a 5000 ml stainless steel beaker and the simethicone was added. The total materials were blended with a spatula until uniform. The resulting granular combinate was lump free, less than 850 microns (20 mesh) in size and contained 40% simethicone.
- VELite 20/40 was charged into a 5 gallon stainless steel Hobart mixer and the simethicone was added. The mixer was energized and mixing was effected for a period of 10 minutes. The resulting granular combinate was found to be lump free, less than 850 microns (20 mesh) in size, and contained 30% simethicone.
- VELite 20/40 was charged into a 20 cubic foot capacity ribbon blender and the simethicone was added. The mixer was energized and mixing was effected for a period of 10 minutes. The resulting granular combinate was discharged into drums and found to be lump free, less than 850 microns (20 mesh) in size, and contained 30% simethicone.
- VELite 20/40 was charged into a 3 cubic foot capacity stainless steel Lodige blender and the simethicone was added. The plow blades of the mixer were energized and mixing effected for a period of 10 minutes. The resulting granular combinate was discharged into a drum and found to be lump free, less than 850 microns (20 mesh) in size, and contained 30% simethicone.
- VELite 20/40 was charged into a 1200 1 stainless steel Lodige blender and the simethicone added.
- the plow blades of the mixer were energized and mixing was effected for a period of 10 minutes.
- the resulting granular combinate was discharged into drums and found to be lump free, less than 850 microns (20 mesh) in size, and contained 30% simethicone.
- simethicone/maltodextrin combinates produced in Examples 1-7 were evaluated in the following manner:
- simethicone/agglomerated maltodextrin combinates produced in Examples 1-7 were evaluated in a typical chewable antacid tablet formulation as follows (all values in mg):
- Each of the formulations were produced as single layer 9/16 inch, flat-faced, beveled edge chewable tablets, compressed at a weight of 1200 mg and a hardness of 7-9 Kp. Tablets with out simethicone were also produced under the same conditions to serve as a control.
- Calcium carbonate-based antacid tablets were prepared with and without simethicone/agglomerated maltodextrin combinate as follows (all values in mg):
- Each of the formulations were processed into single layered 9/16 inch, flat faced, beveled edge chewable tablets compressed at a weight of 1200 mg and a hardness of 7-9 Kp.
- Each of the chewable tablet formulations produced for the trials satisfied the criteria for chewable tablets with respect to taste acceptance, mouth feel, hardness, friability, and acid neutralization.
- Magaldrate (aluminum magnesium hydrate with magnesium sulfate) based antacid tablets were prepared with and without simethicone/agglomerated maltodextrin combinate as follows (all values in mg):
- Both or the formulations were processed into single layered 9/16 inch, flat-faced, beveled edge chewable antacid tablets at a weight of 1200 mg and a hardness of 7-9 Kp.
- the chewable antacid tablets produced for the trials i.e., with and without the simethicone/agglomerated maltodextrin combinate, satisfied the criteria for taste acceptance, mouth feel, hardness, friability, and acid neutralization.
- An antigas chewable tablet formulation was prepared to demonstrate the utility of simethicone/agglomerated maltodextrin combinate in such an application as follows (all values in mg):
- the formulation was produced as a single layered 9/16 inch, flat-faced, beveled edged chewable tablet compressed at a weight of 1200 mg and a hardness of 7-9 Kp.
- the tablets produced satisfied the criteria for taste acceptance, mouth feel, hardness, friability, and foam suppression.
- the VELite 20/40 was charged into a 5 gallon stainless steel Hobart mixer and the fluid silicone oil containing silica added. The mixer was energized and mixing was effected for a period or 10 minutes. The resulting granular combinate was lump free, less than 850 microns (20 mesh) in size and contained 30% of the fluid silicone oil containing silica defoaming compound.
- the VELite 20/40 was charged into a 5 gallon stainless steel Hobart mixer and the fluid mineral oil containing silica added. The mixer was energized and mixing was effected for a period of 10 minutes. The resulting granular combinate was lump free, less than 850 microns (20 mesh) in size and contained 30% of the fluid silicone oil containing silica defoaming compound.
- a granular or agglomerated product comprised of dextrose monohydrate 95% and maltodextrin (10 D.E.) 5% was obtained from Corn Products Corporation under the trademark Unidex 2034.
- the Unidex product had a particle size range of -20/+60 mesh and an apparent bulk density of 0.58 g/cc.
- Sample products were prepared by adding simethicone U.S.P. to the Unidex dextrose monohydrate/maltodextrin mixture in the following amounts, followed by 10 minute mixing to produce relatively free flowing Unidex product/simethicone combinates:
- the Unidex product/simethicone U.S.P. combinates evidenced rapid defoaming characteristics, i.e., 2 seconds by the U.S.P. test.
- Dextrose monohydrate-maltodextrin agglomerates were prepared by fluid bed agglomeration as follows:
- the dextrose monohydrate-maltodextrin co-agglomerate was processed by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the agglomerated dextrose-maltodextrin particles had a particle size range of about -20/+60 mesh and an apparent density of 0.42 g/cc.:
- Sample products were prepared by adding the simethicone U.S.P. to the agglomerated dextrose-maltodextrin in the following amounts (percentages by weight):
- the samples were mixed for 10 minutes to produce relatively free flowing simethicone/dextrose-maltodextrin agglomerate combinates.
- the agglomerated dextrose-maltodextrin/simethicone combinates evidenced rapid defoaming characteristics, i.e., 2 seconds by the U.S.P. defoaming test.
- Sucrose-maltodextrin co-agglomerates were prepared by fluid bed agglomeration as follows:
- sucrose-maltodextrin co-agglomerates was effected by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the sucrose-maltodextrin particles had a particle size range of about -20/+60 mesh and an apparent density of 0.45 g/cc.
- Sample products were prepared by adding simethicone U.S.P. to the sucrose-maltodextrin co-agglomerates in the following amounts:
- the samples were mixed for 10 minutes to produce relatively free flowing simethicone/sucrose-maltodextrin agglomerate combinates.
- sucrose-maltodextrin/simethicone combinates evidenced rapid defoaming characteristics, i.e., 2 seconds by the U.S.P. defoaming test.
- Standard single layer chewable antacid tablets containing 200 mg aluminum hydroxide, 200 mg magnesium hydroxide, and 25 mg of simethicone in the form of the sucrose-maltodextrin co-agglomerate/simethicone combinate also evidenced satisfactory defoaming characteristics when tested by the U.S.P. defoaming method, i.e., 6-8 seconds.
- Sucrose 10x-maltodextrin co-agglomerates were prepared by fluid bed agglomeration as follows.
- Sucrose-10X is a widely available finely milled sucrose which contains 2% corn starch to assure free-flow:
- sucrose 10X-maltodextrin co-agglomerate was effected by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the agglomerated sucrose 10X-maltodextrin particles had a particle size range of about -20/+60 mesh and an apparent density of 0.40 g/cc.
- Sample products were prepared by adding the simethicone U.S.P. to the sucrose 10X-maltodextrin agglomerate in the following amounts:
- the samples were produced by mixing for 10 minutes to produce relatively free flowing simethicone/sucrose 10X-maltodextrin agglomerate combinates
- sucrose 10X-maltodextrin/simethicone U.S.P. combinates evidenced rapid defoaming characteristics, i.e. 2 seconds by the U.S.P. defoaming test.
- Dextrose monohydrate-maltodextrin co-agglomerates were prepared by fluid bed agglomeration as follows:
- the dextrose monohydrate-maltodextrin co-agglomerate was effected by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the dextrose-maltodextrin co-agglomerate particles had a particle size range of about -20/+60 mesh and an apparent density of 0.30 g/cc.
- Sample products were prepared by adding the simethicone U.S.P. to the dextrose-maltodextrin co-agglomerate in the following amounts:
- the samples were produced by mixing for 10 minutes to produce relatively free flowing simethicone/dextrose-maltodextrin co-agglomerate combinates.
- the agglomerated dextrose-maltodextrin/simethicone U.S.P. combinates evidenced rapid defoaming characteristics, i.e. 2 seconds by the U.S.P. defoaming test.
- Sucrose-maltodextrin co-agglomerates were prepared by fluid bed agglomeration as follows:
- sucrose-maltodextrin co-agglomerate was effected by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the sucrose-maltodextrin co-agglomerate particles had a particle size range of about -20/+60 mesh and an apparent density of 0.32 g/cc.
- Sample products were prepared by adding simethicone U.S.P. to the sucrose-maltodextrin co-agglomerates in the following amounts:
- the samples were produced by mixing for 10 minutes to produce relatively free flowing simethicone/sucrose-maltodextrin co-agglomerate combinates.
- sucrose-maltodextrin co-agglomerate/simethicone combinates evidenced rapid defoaming characteristics, i.e. 2 seconds by the U.S.P. defoaming test.
- Dextrose monohydrate-maltodextrin co-agglomerates were prepared as in Example 19 except that the pump solution was 5% povidone (K 29/32) U.S.P.
- Sucrose-maltodextrin co-agglomerates were prepared as in example 20 except that the pump solution was 5% povidone (K 29/32) U.S.P.
- Fructose-maltodextrin co-agglomerates were prepared by fluid bed agglomeration as follows:
- a fructose-maltodextrin co-agglomerate was effected by standard spray granulation techniques to produce an agglomerate for sorption trials. After processing, the fructose-maltodextrin co-agglomerate particles had a particle size range of about -20/+60 mesh and an apparent density of 0.42 g/cc.
- Sample products were prepared by adding simethicone U.S.P. to the fructose-maltodextrin agglomerates in the following amounts:
- the samples were produced by mixing for 10 minutes to produce relatively free flowing simethicone/fructose-maltodextrin co-agglomerate combinates.
- the co-agglomerated fructose-maltodextrin/simethicone combinates evidenced rapid defoaming characteristics, i.e. 2 seconds by the U.S.P. defoaming-test.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(CH.sub.3).sub.3 Si OSi(CH.sub.3).sub.2 !.sub.n CH.sub.3 +SiO.sub.2
______________________________________ Quantity of the Simethicone Time to Example Combinate Used Equivalent Defoam No. (mg) (mg) (sec.) ______________________________________ 1 10.0 2 3-4 2 6.7 2 3-4 3 5.0 2 3-4 4 6.7 2 3-4 5 6.7 2 3-4 6 6.7 2 3-4 7 6.7 2 3-4 Controls- Simethicone U.S.P 2.0 2 3-4 Simethicone U.S.P 6.7 2 3-4 (as 30% emulsion) ______________________________________
______________________________________ EX. EX. EX. EX. EX. EX. EX. 1 2 3 4 5 6 7 ______________________________________ Compression 661 702 723 702 702 702 702 Dextrose Aluminum 200 200 200 200 200 200 200 Hydroxide Dried Gel Magnesium 200 200 200 200 200 200 200 Hydroxide Powder Simethicone/ 125 84 63 84 84 84 84 Maltodextrin Combinate Equivalent to 25 mg of Simethicone Spray Dried 5 5 5 5 5 5 5 Flavor Magnesium 9 9 9 9 9 9 9 Stearate ______________________________________
______________________________________ Test Storage Condition: Tablets produced with Initial 45° for 2 Months Simethicone/Malto- Time to Defoam Time to Defoam dextrin Combinate From: (In Seconds) (In Seconds) ______________________________________ EX. 1 5-7 5-7 EX. 2 5-7 5-7 EX. 3 5-7 5-7 EX. 4 5-7 5-7 EX. 5 5-7 5-7 EX. 6 5-7 5-7 EX. 7 5-7 5-7 Control No Defoaming No Defoaming ______________________________________
______________________________________ With Without Formula: Combinate Combinate ______________________________________ Calcium Carbonate 1000 1000 Compression Granules (53% Calcium Carbonate 47% Dextrose) Compression Dextrose 104 188 Simethicone/Agglomerated 84 -- Maltodextrin Combinate From Example #7 Spray Dried Flavor 3 3 Magnesium Stearate 9 9 ______________________________________
______________________________________ Defoaming Time ______________________________________ Formulation With Combinate 4-6 sec. Formulation Without Combinate No Defoaming ______________________________________
______________________________________ With Without Formula Combinate Combinate ______________________________________ Dextrose Compression 702 786 Granules Magaldrate 400 400 Simethicone/Agglomerated 84 -- Maltodextrin Combinate From Example 7 Spray Dried Flavor 5 5 Magnesium Stearate 9 9 ______________________________________
______________________________________ Defoaming Time ______________________________________ Formulation With Combinate 4-6 sec. Formulation Without Combinate No Defoaming ______________________________________
______________________________________ 1 2 3 ______________________________________ Unidex 2034 80% w/w 70% w/w 60% w/w (-20/+60 Mesh) Sentry Simethicone U.S.P. 20% w/w 30% w/w 40% w/w (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Dextrose/maltodextrin 80% 70% 60% Co-agglomerate (-20/+60 Mesh) Sentry Simethicone U.S.P. 20% 30% 40% (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Sucrose-maltodextrin 80% 70% 60% co-agglomerate (-20/+60 Mesh) Sentry Simethicone U.S.P. 20% 30% 40% (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Sucrose 10X-maltodextrin 80% 70% 60% Co-agglomerate (-20/+60 Mesh) Sentry Simethicone U.S.P. 20% 30% 40% (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Dextrose-maltodextrin 80% 70% 60% Co-agglomerate (-20/+60 Mesh) Sentry simethicone U.S.P. 20% 30% 40% (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Sucrose-maltodextrin 80% 70% 60% co-agglomerate (-20/+60 Mesh) Sentry Simethicone 20% 30% 40% (Union Carbide) ______________________________________
______________________________________ 1 2 3 ______________________________________ Fructose/maltodextrin 80% 70% 60% co-agglomerate (-20/+60 Mesh) Sentry Simethicone U.S.P. 20% 30% 40% (Union Carbide) ______________________________________
Claims (61)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/374,224 USRE35893E (en) | 1989-10-19 | 1995-01-18 | Defoaming composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/423,877 US5073384A (en) | 1989-10-19 | 1989-10-19 | Maltodextrin/defoaming composition combinate |
US07/806,581 US5275822A (en) | 1989-10-19 | 1991-12-12 | Defoaming composition |
US08/374,224 USRE35893E (en) | 1989-10-19 | 1995-01-18 | Defoaming composition |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/423,877 Continuation-In-Part US5073384A (en) | 1989-10-19 | 1989-10-19 | Maltodextrin/defoaming composition combinate |
US07/806,581 Reissue US5275822A (en) | 1989-10-19 | 1991-12-12 | Defoaming composition |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE35893E true USRE35893E (en) | 1998-09-08 |
Family
ID=27026167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/374,224 Expired - Lifetime USRE35893E (en) | 1989-10-19 | 1995-01-18 | Defoaming composition |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE35893E (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6129906A (en) | 1995-11-11 | 2000-10-10 | The Procter & Gamble Company | Silicone containing powders |
US6303663B1 (en) | 1999-03-26 | 2001-10-16 | Cognis Corporation | Process for making defoaming compositions |
US20030211961A1 (en) * | 2001-01-18 | 2003-11-13 | Lai Kuo-Tsai G. | Anti-foam composition |
Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2441098A (en) * | 1946-09-09 | 1948-05-04 | Corning Glass Works | Methyl siloxane polymers and method of preparation |
CA508856A (en) * | 1955-01-04 | Shell Development Company | Non-foaming detergents | |
US2774710A (en) * | 1952-12-15 | 1956-12-18 | Organon | Pharmaceutical preparation for the treatment of hyperacidity |
US3076768A (en) * | 1959-07-20 | 1963-02-05 | Hercules Powder Co Ltd | Defoamer |
US3207698A (en) * | 1963-02-13 | 1965-09-21 | Nopco Chem Co | Composition and method for defoaming aqueous systems |
US3304266A (en) * | 1963-05-06 | 1967-02-14 | Dow Corning | Foam control agents |
US3326754A (en) * | 1965-06-10 | 1967-06-20 | Rexall Drug Chemical | Method of relieving gastrointestinal distress with tributyl phosphate |
US3388073A (en) * | 1963-12-16 | 1968-06-11 | Nalco Chemical Co | Process of defoaming and inhibiting foam formation in aqueous systems |
GB1166877A (en) * | 1967-05-24 | 1969-10-15 | Buckman Labor Inc | A Defoaming, Deaerating and Drainage Aid Composition and Process For The Preparation Thereof |
US3501571A (en) * | 1965-12-06 | 1970-03-17 | Smithkline Corp | Novel silicone compositions and method of preparing same |
GB1267482A (en) * | 1969-07-16 | 1972-03-22 | Bayer Ag | Defoaming agents |
US3663369A (en) * | 1968-02-23 | 1972-05-16 | Grain Processing Corp | Hydrolysis of starch |
US3691091A (en) * | 1969-03-22 | 1972-09-12 | Goldschmidt Ag Th | Defoaming emulsion |
US3705859A (en) * | 1970-12-30 | 1972-12-12 | Hercules Inc | Method of abating foam formation in aqueous systems |
US3714068A (en) * | 1970-12-28 | 1973-01-30 | Philadelphia Quartz Co | Silica |
US3746653A (en) * | 1972-05-15 | 1973-07-17 | Dow Corning | Jet dyeing foam control |
US3767794A (en) * | 1969-11-21 | 1973-10-23 | Richardson Merrell Inc | Antifoam preparations and method of preparing same |
US3784479A (en) * | 1972-05-15 | 1974-01-08 | Dow Corning | Foam control composition |
US3843558A (en) * | 1971-07-01 | 1974-10-22 | Dow Corning Ltd | Foam control substance |
US3849194A (en) * | 1966-12-19 | 1974-11-19 | Cpc International Inc | Low d.e. starch conversion products |
US3909445A (en) * | 1970-03-18 | 1975-09-30 | Mobil Oil Corp | Method for reducing foam in water containing systems |
US3912652A (en) * | 1973-12-17 | 1975-10-14 | Dow Corning | Defoaming composition useful in jet dyeing |
US3959176A (en) * | 1974-09-09 | 1976-05-25 | Drew Chemical Corporation | Non-foaming dispersing composition |
US4102823A (en) * | 1972-12-08 | 1978-07-25 | The Procter & Gamble Company | Low and non-phosphate detergent compositions |
US4115553A (en) * | 1973-12-10 | 1978-09-19 | Armour Pharmaceutical Company | Antacid tablets |
US4127650A (en) * | 1975-03-31 | 1978-11-28 | William H. Rorer, Inc. | Medicinal simethicone containing composition and its method of production |
US4180485A (en) * | 1977-11-02 | 1979-12-25 | The Procter & Gamble Company | Spray-dried detergent compositions |
US4230693A (en) * | 1975-04-21 | 1980-10-28 | Armour-Dial, Inc. | Antacid tablets and processes for their preparation |
US4264465A (en) * | 1978-06-07 | 1981-04-28 | Ciba-Geigy Corporation | Process for the preparation of foam-controlled detergents |
USRE30880E (en) * | 1967-03-24 | 1982-03-09 | Grain Processing Corporation | Low D.E. starch conversion products |
US4386106A (en) * | 1981-12-01 | 1983-05-31 | Borden, Inc. | Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition |
JPS5895496A (en) * | 1981-12-02 | 1983-06-07 | Nippon Telegr & Teleph Corp <Ntt> | Production for piezoelectric electro-acoustic transducer |
US4396604A (en) * | 1982-05-17 | 1983-08-02 | Norcliff Thayer, Inc. | Simethicone antacid lozenge |
JPS59164551A (en) * | 1983-03-08 | 1984-09-17 | Fuji Photo Film Co Ltd | Image forming method |
US4497832A (en) * | 1983-04-18 | 1985-02-05 | Warner-Lambert Company | Chewing gum composition having enhanced flavor-sweetness |
US4514319A (en) * | 1983-03-25 | 1985-04-30 | Union Carbide Corporation | Antifoam composition containing hydrocarbon-silicon copolymer, hydrophobic filler and hydrocarbon oil |
US4581381A (en) * | 1983-11-14 | 1986-04-08 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
US4590075A (en) * | 1984-08-27 | 1986-05-20 | Warner-Lambert Company | Elastomer encapsulation of flavors and sweeteners, long lasting flavored chewing gum compositions based thereon and process of preparation |
US4605551A (en) * | 1984-11-30 | 1986-08-12 | William H. Rorer, Inc. | Dry oil coated antacid process |
EP0213953A2 (en) * | 1985-09-04 | 1987-03-11 | Unilever Plc | Antifoam ingredient for detergent compositions |
US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
US4698264A (en) * | 1982-08-02 | 1987-10-06 | Durkee Industrial Foods, Corp. | Particulate composition and process for making same |
US4804543A (en) * | 1987-07-14 | 1989-02-14 | Warner-Lambert Company | Novel hydrophilic plasticizing system and chewing gum containing same |
US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
US5004595A (en) * | 1986-12-23 | 1991-04-02 | Warner-Lambert Company | Multiple encapsulated flavor delivery system and method of preparation |
US5024937A (en) * | 1989-04-06 | 1991-06-18 | Dow Corning Corporation | Method for processing aqueous fermentation broths |
US5078888A (en) * | 1989-04-06 | 1992-01-07 | Dow Corning Corporation | Method for processing aqueous fermentation broths |
-
1995
- 1995-01-18 US US08/374,224 patent/USRE35893E/en not_active Expired - Lifetime
Patent Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA508856A (en) * | 1955-01-04 | Shell Development Company | Non-foaming detergents | |
US2441098A (en) * | 1946-09-09 | 1948-05-04 | Corning Glass Works | Methyl siloxane polymers and method of preparation |
US2774710A (en) * | 1952-12-15 | 1956-12-18 | Organon | Pharmaceutical preparation for the treatment of hyperacidity |
US3076768A (en) * | 1959-07-20 | 1963-02-05 | Hercules Powder Co Ltd | Defoamer |
US3207698A (en) * | 1963-02-13 | 1965-09-21 | Nopco Chem Co | Composition and method for defoaming aqueous systems |
US3304266A (en) * | 1963-05-06 | 1967-02-14 | Dow Corning | Foam control agents |
US3388073A (en) * | 1963-12-16 | 1968-06-11 | Nalco Chemical Co | Process of defoaming and inhibiting foam formation in aqueous systems |
US3326754A (en) * | 1965-06-10 | 1967-06-20 | Rexall Drug Chemical | Method of relieving gastrointestinal distress with tributyl phosphate |
US3501571A (en) * | 1965-12-06 | 1970-03-17 | Smithkline Corp | Novel silicone compositions and method of preparing same |
US3849194A (en) * | 1966-12-19 | 1974-11-19 | Cpc International Inc | Low d.e. starch conversion products |
USRE30880E (en) * | 1967-03-24 | 1982-03-09 | Grain Processing Corporation | Low D.E. starch conversion products |
GB1166877A (en) * | 1967-05-24 | 1969-10-15 | Buckman Labor Inc | A Defoaming, Deaerating and Drainage Aid Composition and Process For The Preparation Thereof |
US3663369A (en) * | 1968-02-23 | 1972-05-16 | Grain Processing Corp | Hydrolysis of starch |
US3691091A (en) * | 1969-03-22 | 1972-09-12 | Goldschmidt Ag Th | Defoaming emulsion |
GB1267482A (en) * | 1969-07-16 | 1972-03-22 | Bayer Ag | Defoaming agents |
US3767794A (en) * | 1969-11-21 | 1973-10-23 | Richardson Merrell Inc | Antifoam preparations and method of preparing same |
US3909445A (en) * | 1970-03-18 | 1975-09-30 | Mobil Oil Corp | Method for reducing foam in water containing systems |
US3714068A (en) * | 1970-12-28 | 1973-01-30 | Philadelphia Quartz Co | Silica |
US3705859A (en) * | 1970-12-30 | 1972-12-12 | Hercules Inc | Method of abating foam formation in aqueous systems |
US3843558A (en) * | 1971-07-01 | 1974-10-22 | Dow Corning Ltd | Foam control substance |
US3746653A (en) * | 1972-05-15 | 1973-07-17 | Dow Corning | Jet dyeing foam control |
US3784479A (en) * | 1972-05-15 | 1974-01-08 | Dow Corning | Foam control composition |
US3865544A (en) * | 1972-05-15 | 1975-02-11 | Dow Chemical Co | Dyeing with foam control composition of silica, polyoxypropylenes and polydimethylsiloxane |
US4102823A (en) * | 1972-12-08 | 1978-07-25 | The Procter & Gamble Company | Low and non-phosphate detergent compositions |
US4115553A (en) * | 1973-12-10 | 1978-09-19 | Armour Pharmaceutical Company | Antacid tablets |
US3912652A (en) * | 1973-12-17 | 1975-10-14 | Dow Corning | Defoaming composition useful in jet dyeing |
US3959176A (en) * | 1974-09-09 | 1976-05-25 | Drew Chemical Corporation | Non-foaming dispersing composition |
US4127650A (en) * | 1975-03-31 | 1978-11-28 | William H. Rorer, Inc. | Medicinal simethicone containing composition and its method of production |
US4230693A (en) * | 1975-04-21 | 1980-10-28 | Armour-Dial, Inc. | Antacid tablets and processes for their preparation |
US4180485A (en) * | 1977-11-02 | 1979-12-25 | The Procter & Gamble Company | Spray-dried detergent compositions |
US4264465A (en) * | 1978-06-07 | 1981-04-28 | Ciba-Geigy Corporation | Process for the preparation of foam-controlled detergents |
US4386106A (en) * | 1981-12-01 | 1983-05-31 | Borden, Inc. | Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition |
JPS5895496A (en) * | 1981-12-02 | 1983-06-07 | Nippon Telegr & Teleph Corp <Ntt> | Production for piezoelectric electro-acoustic transducer |
US4396604A (en) * | 1982-05-17 | 1983-08-02 | Norcliff Thayer, Inc. | Simethicone antacid lozenge |
US4698264A (en) * | 1982-08-02 | 1987-10-06 | Durkee Industrial Foods, Corp. | Particulate composition and process for making same |
JPS59164551A (en) * | 1983-03-08 | 1984-09-17 | Fuji Photo Film Co Ltd | Image forming method |
US4514319A (en) * | 1983-03-25 | 1985-04-30 | Union Carbide Corporation | Antifoam composition containing hydrocarbon-silicon copolymer, hydrophobic filler and hydrocarbon oil |
US4497832A (en) * | 1983-04-18 | 1985-02-05 | Warner-Lambert Company | Chewing gum composition having enhanced flavor-sweetness |
US4581381A (en) * | 1983-11-14 | 1986-04-08 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
US4590075A (en) * | 1984-08-27 | 1986-05-20 | Warner-Lambert Company | Elastomer encapsulation of flavors and sweeteners, long lasting flavored chewing gum compositions based thereon and process of preparation |
US4605551A (en) * | 1984-11-30 | 1986-08-12 | William H. Rorer, Inc. | Dry oil coated antacid process |
US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
EP0213953A2 (en) * | 1985-09-04 | 1987-03-11 | Unilever Plc | Antifoam ingredient for detergent compositions |
US5004595A (en) * | 1986-12-23 | 1991-04-02 | Warner-Lambert Company | Multiple encapsulated flavor delivery system and method of preparation |
US4804543A (en) * | 1987-07-14 | 1989-02-14 | Warner-Lambert Company | Novel hydrophilic plasticizing system and chewing gum containing same |
US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
US5024937A (en) * | 1989-04-06 | 1991-06-18 | Dow Corning Corporation | Method for processing aqueous fermentation broths |
US5078888A (en) * | 1989-04-06 | 1992-01-07 | Dow Corning Corporation | Method for processing aqueous fermentation broths |
Non-Patent Citations (3)
Title |
---|
Literature for Union Carbide product "Sentry Simethicone GS", published Oct. 1990, two pages. |
Literature for Union Carbide product Sentry Simethicone GS , published Oct. 1990, two pages. * |
Patent Abstracts of Japan vol. 1, No. 199, Jul. 11, 1986; p. 105, C 359. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6129906A (en) | 1995-11-11 | 2000-10-10 | The Procter & Gamble Company | Silicone containing powders |
US6303663B1 (en) | 1999-03-26 | 2001-10-16 | Cognis Corporation | Process for making defoaming compositions |
US20030211961A1 (en) * | 2001-01-18 | 2003-11-13 | Lai Kuo-Tsai G. | Anti-foam composition |
US6949499B2 (en) | 2001-01-18 | 2005-09-27 | General Electric Company | Anti-foam composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5275822A (en) | Defoaming composition | |
US5073384A (en) | Maltodextrin/defoaming composition combinate | |
US4906478A (en) | Simethicone/calcium silicate composition | |
CA1083964A (en) | Pharmaceutical composition containing sodium alginate | |
US5167965A (en) | Palatable cholestyramine granules, tablets and methods for preparation thereof | |
CA1313135C (en) | Cholestyramine composition and process for its preparation | |
US8895141B2 (en) | Excipient for compressed tablets comprising novel spherical mannitol | |
KR100358211B1 (en) | Granule products or tablets containing foaming systems and pharmaceutical active substances and methods for making them | |
US3946110A (en) | Medicinal compositions and methods of preparing the same | |
EP0104167A1 (en) | Psyllium compositions. | |
NO321771B1 (en) | Excipient composition, aqueous slurry composition and process for preparing an excipient. | |
EP0891776A1 (en) | Simethicone/anhydrous calcium phosphate compositions | |
US5458886A (en) | Antifoam compositions | |
USRE35893E (en) | Defoaming composition | |
US2951011A (en) | Silicone composition for the relief of gastro-intestinal distress and method of using same | |
US6716885B1 (en) | Storage-stable aerated gel composition and a process for producing it | |
EP0119479B1 (en) | Dry mix cellulose ether compositions as bulk laxatives | |
US5633005A (en) | Dimeticon pastilles | |
US4837029A (en) | Low foaming, aqueously homogenizable rifampin composition | |
JPH08512061A (en) | Sustained release excipient | |
JP2005255619A (en) | Solid pharmaceutical preparation composition comprising sublimable active ingredient and porous cellulose particle | |
KR100442174B1 (en) | The novel composition of defoaming agent | |
JPH07173068A (en) | Laxative composition containing lactobacillus | |
AU5830399A (en) | Pharmaceutical excipient having improved compressibility | |
MXPA98005755A (en) | Simethicone/anhydrous calcium phosphate compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED TECHNOLOGY PHARMACEUTICALS CORP., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VALENTINE ENTERPRISES, INC.;REEL/FRAME:008723/0236 Effective date: 19970915 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT, Free format text: SECURITY AGREEMENT;ASSIGNORS:MOMENTIVE PERFORMANCE MATERIALS HOLDINGS INC.;MOMENTIVE PERFORMANCE MATERIALS GMBH & CO. KG;MOMENTIVE PERFORMANCE MATERIALS JAPAN HOLDINGS GK;REEL/FRAME:019511/0166 Effective date: 20070228 |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC COMPANY,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CROMPTON CORPORATION;REEL/FRAME:020072/0289 Effective date: 20030731 Owner name: GENERAL ELECTRIC COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CROMPTON CORPORATION;REEL/FRAME:020072/0289 Effective date: 20030731 |
|
AS | Assignment |
Owner name: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., A Free format text: SECURITY AGREEMENT;ASSIGNORS:MOMENTIVE PERFORMANCE MATERIALS, INC.;JUNIPER BOND HOLDINGS I LLC;JUNIPER BOND HOLDINGS II LLC;AND OTHERS;REEL/FRAME:022902/0461 Effective date: 20090615 |
|
AS | Assignment |
Owner name: MOMENTIVE PERFORMANCE MATERIALS GMBH & CO KG, GERMANY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:054387/0001 Effective date: 20201102 Owner name: MOMENTIVE PERFORMANCE MATERIALS JAPAN HOLDINGS GK, JAPAN Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:054387/0001 Effective date: 20201102 Owner name: MOMENTIVE PERFORMANCE MATERIALS INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:054387/0001 Effective date: 20201102 |
|
AS | Assignment |
Owner name: MOMENTIVE PERFORMANCE MATERIALS INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS COLLATERAL AGENT;REEL/FRAME:054883/0855 Effective date: 20201222 |